Gyre Therapeutics (GYRE) Total Current Liabilities (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Total Current Liabilities of $19.8 million for Q1 2026, up 4.2% year-over-year from $19.0 million in Q1 2025, and up 8.21% quarter-over-quarter from $18.3 million in Q4 2025.
Gyre Therapeutics (GYRE) Total Current Liabilities (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Total Current Liabilities for 17 consecutive years, with $19.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 4.2% year-over-year to $19.8 million; the TTM figure through Mar 2026 stood at $19.8 million (up 4.2% YoY), while the FY2025 annual figure was $18.3 million, down 6.3% from the prior year.
- Total Current Liabilities improved to $19.8 million in Q1 2026 per GYRE's latest filing, from $18.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $20.0 million in Q4 2023 and bottomed at $1.6 million in Q3 2022.
- Historically, Total Current Liabilities has averaged $13.1 million across 5 years, with a median of $15.6 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities sank 90.47% — and 2024, when it surged 725.35%.
- Gyre Therapeutics' Total Current Liabilities stood at $12.2 million in 2022, then surged by 63.76% to $20.0 million in 2023, then fell by 2.65% to $19.5 million in 2024, then declined by 6.3% to $18.3 million in 2025, then climbed by 8.21% to $19.8 million in 2026.
- Business Quant data shows GYRE's Total Current Liabilities at $19.8 million in Q1 2026, $18.3 million in Q4 2025, and $15.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 28.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.66 Mn |
| Mar 31, 2026 | 19.79 Mn |
| Dec 31, 2025 | 18.29 Mn |
| Sep 30, 2025 | 15.91 Mn |
| Jun 30, 2025 | 16.92 Mn |
| Mar 31, 2025 | 18.99 Mn |
| Dec 31, 2024 | 19.52 Mn |
| Sep 30, 2024 | 14.72 Mn |
| Jun 30, 2024 | 15.57 Mn |
| Mar 31, 2024 | 19.49 Mn |
| Dec 31, 2023 | 20.05 Mn |
| Sep 30, 2023 | 1.78 Mn |
| Jun 30, 2023 | 2.79 Mn |
| Mar 31, 2023 | 6.84 Mn |
| Dec 31, 2022 | 12.24 Mn |
| Sep 30, 2022 | 1.64 Mn |
| Jun 30, 2022 | 4.31 Mn |
| Mar 31, 2022 | 13.19 Mn |
| Dec 31, 2021 | 14.17 Mn |
| Sep 30, 2021 | 17.25 Mn |